Levy-Mendelovich S, Lev A, Rechavi E, Barel O, Golan H, Bielorai B, Neumann Y, Simon A J, Somech R
Pediatric Department A and the Immunology Service, Jeffrey Modell Foundation Center, "Edmond and Lily Safra" Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Department of Pediatric Hematology-Oncology and BMT, "Edmond and Lily Safra" Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Clin Exp Immunol. 2017 Sep;189(3):310-317. doi: 10.1111/cei.12986. Epub 2017 Jun 5.
Ras-associated lymphoproliferative disease (RALD) is an autoimmune lymphoproliferative syndrome (ALPS)-like disease caused by mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) or neuroblastoma RAS viral (V-Ras) oncogene homologue (NRAS). The immunological phenotype and pathogenesis of RALD have yet to be studied extensively. Here we report a thorough immunological investigation of a RALD patient with a somatic KRAS mutation. Patient lymphocytes were analysed for phenotype, immunoglobulin levels and T cell proliferation capacity. T and B cell receptor excision circles (TREC and KREC, respectively), markers of naive T and B cell production, were measured serially for 3 years. T and B cell receptor repertoires were studied using both traditional assays as well as next-generation sequencing (NGS). TREC and KREC declined dramatically with time, as did T cell receptor diversity. NGS analysis demonstrated T and B clonal expansions and marked restriction of T and B cell receptor repertoires compared to healthy controls. Our results demonstrate, at least for our reported RALD patient, how peripheral T and B clonal expansions reciprocally limit lymphocyte production and restrict the lymphocyte receptor repertoire in this disease. Decreased naive lymphocyte production correlated with a clinical deterioration in our patient's immune status, suggesting that TREC and KREC may be used as an aid in monitoring disease progression. Both the methodologies used here and the conclusions regarding immune homeostasis may be applicable to the research of ALPS and other immune dysregulation syndromes.
Ras相关淋巴细胞增殖性疾病(RALD)是一种类似自身免疫性淋巴细胞增殖综合征(ALPS)的疾病,由 Kirsten 大鼠肉瘤病毒癌基因同源物(KRAS)或神经母细胞瘤RAS病毒(V-Ras)癌基因同源物(NRAS)的突变引起。RALD的免疫表型和发病机制尚未得到广泛研究。在此,我们报告了对一名患有体细胞KRAS突变的RALD患者进行的全面免疫学调查。对患者淋巴细胞进行了表型、免疫球蛋白水平和T细胞增殖能力分析。连续3年测量了幼稚T和B细胞产生的标志物T和B细胞受体切除环(分别为TREC和KREC)。使用传统检测方法以及下一代测序(NGS)研究了T和B细胞受体库。TREC和KREC随时间急剧下降,T细胞受体多样性也是如此。NGS分析表明,与健康对照相比,T和B细胞存在克隆性扩增,且T和B细胞受体库明显受限。我们的结果表明,至少对于我们报道的RALD患者,外周T和B细胞克隆性扩增如何相互限制淋巴细胞产生并限制该疾病中的淋巴细胞受体库。幼稚淋巴细胞产生减少与我们患者免疫状态的临床恶化相关,这表明TREC和KREC可用于辅助监测疾病进展。本文使用的方法以及关于免疫稳态的结论可能适用于ALPS和其他免疫失调综合征的研究。